Lifestyle First and Lifestyle Always, Does Not Mean Lifestyle Only: Reimagining Cardiometabolic Care in the Era of GLP-1 Receptor Agonists - PubMed

2 hours ago

GLP-1 receptor agonists have revolutionized obesity, diabetes, and cardiometabolic disease management, offering weight loss, glycemic control, and reduced cardiovascular and renal risks.
The article advocates for 'lifestyle first and lifestyle always, but not lifestyle only,' emphasizing that pharmacotherapy alone cannot address the full spectrum of behavioral, physiological, and social risk factors.
Discontinuing GLP-1 RAs without lifestyle support often leads to weight regain and fails to tackle issues like sarcopenia, physical deconditioning, sleep, stress, and psychosocial determinants.
Lifestyle behaviors—including nutrition, physical activity (especially resistance training), sleep, stress management, social connectedness, and purpose—are crucial for durable health improvements.
GLP-1 RAs should serve as catalysts to facilitate lifestyle changes rather than replacements, promoting conditions favorable for adopting and sustaining healthy behaviors.
Integrated, interprofessional models combining pharmacologic and lifestyle strategies, supported by policy and systems change, are proposed as the new standard for long-term cardiometabolic care.

Hasty Briefsbeta